Medical research demonstrates the powerful therapeutic uses of psilocybin in the treatment of anxiety and depression associated with terminal illness. The state and federal “Right to Try” (RTT) acts are intended to allow terminally ill patients access to drugs still in investigational stages, recognizing that such patients do not have the luxury of time to await the slow process of new drug approval. Psilocybin qualifies as such a drug and all other requirements. DEA has refused to accommodate RTT denying Sunil Aggarwal,…